94 related articles for article (PubMed ID: 10470182)
21. Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma.
Stroescu C; Dragnea A; Ivanov B; Pechianu C; Herlea V; Sgarbura O; Popescu A; Popescu I
J Gastrointestin Liver Dis; 2008 Dec; 17(4):411-7. PubMed ID: 19104702
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of CD44 and c-erb-B2 protein overexpression in patients with gastric cancer.
Doventas A; Bilici A; Demirell F; Ersoy G; Turna H; Doventas Y
Hepatogastroenterology; 2012 Oct; 59(119):2196-201. PubMed ID: 23435135
[TBL] [Abstract][Full Text] [Related]
23. Number and tumor size are not sufficient criteria to select patients for liver transplantation for hepatocellular carcinoma.
Piardi T; Gheza F; Ellero B; Woehl-Jaegle ML; Ntourakis D; Cantu M; Marzano E; Audet M; Wolf P; Pessaux P
Ann Surg Oncol; 2012 Jun; 19(6):2020-6. PubMed ID: 22179632
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols.
Borg A; Lennerstrand J; Stenmark-Askmalm M; Fernö M; Brisfors A; Ohrvik A; Stål O; Killander D; Lane D; Brundell J
Br J Cancer; 1995 May; 71(5):1013-7. PubMed ID: 7734292
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt.
el-A Helal T; Khalifa A; Kamel AS
Anticancer Res; 2000; 20(3B):2145-50. PubMed ID: 10928168
[TBL] [Abstract][Full Text] [Related]
26. Tumour staging, morphology and p53 overexpression concur in predicting survival in hepatocellular carcinoma.
Gianni S; Cecchetto A; Altavilla G; Ragazzi R; Bertazzo M; De Giorgio M; Baldan A; Fagiuoli S; Farinati F
J Intern Med; 2005 Apr; 257(4):367-73. PubMed ID: 15788007
[TBL] [Abstract][Full Text] [Related]
27. The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan.
Hayashi H; Sugio K; Matsumata T; Adachi E; Takenaka K; Sugimachi K
Hepatology; 1995 Dec; 22(6):1702-7. PubMed ID: 7489977
[TBL] [Abstract][Full Text] [Related]
28. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma.
Nakanishi K; Sakamoto M; Yamasaki S; Todo S; Hirohashi S
Cancer; 2005 Jan; 103(2):307-12. PubMed ID: 15593087
[TBL] [Abstract][Full Text] [Related]
29. Prognosis in patients with hepatocellular carcinoma correlates to mutations of p53 and/or hMSH2 genes.
Yano M; Hamatani K; Eguchi H; Hirai Y; MacPhee DG; Sugino K; Dohi K; Itamoto T; Asahara T
Eur J Cancer; 2007 Apr; 43(6):1092-100. PubMed ID: 17350822
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of TP53 protein accumulation in human primary breast cancer: an analysis by luminometric immunoassay on 1491 tumor cytosols.
Berns EM; De Witte HH; Klijn JG; Willman K; Look MP; Meijer-Van Gelder ME; Benraad TJ; Foekens JA
Anticancer Res; 1997; 17(4B):3003-6. PubMed ID: 9329586
[TBL] [Abstract][Full Text] [Related]
31. Expression of hepatoma-derived growth factor in hepatocellular carcinoma.
Hu TH; Huang CC; Liu LF; Lin PR; Liu SY; Chang HW; Changchien CS; Lee CM; Chuang JH; Tai MH
Cancer; 2003 Oct; 98(7):1444-56. PubMed ID: 14508832
[TBL] [Abstract][Full Text] [Related]
32. C-erb-B2 gene amplification and serum level of c-erb-B2 oncoprotein at primary breast cancer diagnosis.
Fontana X; Ferrari P; Namer M; Peysson R; Salanon C; Bussiere F
Anticancer Res; 1994; 14(5B):2099-104. PubMed ID: 7840506
[TBL] [Abstract][Full Text] [Related]
33. Influence of the c-erb B-2, nm23, bcl-2 and p53 protein markers on colorectal cancer.
Demirbaş S; Sücüllü I; Yildirim S; Celenk T
Turk J Gastroenterol; 2006 Mar; 17(1):13-9. PubMed ID: 16830272
[TBL] [Abstract][Full Text] [Related]
34. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma.
Ueki T; Fujimoto J; Suzuki T; Yamamoto H; Okamoto E
Hepatology; 1997 Apr; 25(4):862-6. PubMed ID: 9096589
[TBL] [Abstract][Full Text] [Related]
35. Value of c-erbB-2 and p53 oncoprotein co-overexpression in human breast cancer.
Barbati A; Cosmi EV; Sidoni A; Collini P; Porpora MG; Ferri I; Lüthy M; Lauro V; Bucciarelli E
Anticancer Res; 1997; 17(1A):401-5. PubMed ID: 9066684
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of p53 in hepatocellular carcinomas: a clinicopathological and prognostic correlation.
Ng IO; Lai EC; Chan AS; So MK
J Gastroenterol Hepatol; 1995; 10(3):250-5. PubMed ID: 7548799
[TBL] [Abstract][Full Text] [Related]
37. [Loss of p53 gene and amplification of HER-2 oncogene in primary hepatocellular carcinoma and their clinical significance].
Huang BJ; Zhu ZY; Liang QW; Fang Y
Zhonghua Bing Li Xue Za Zhi; 2003 Feb; 32(1):20-4. PubMed ID: 12760798
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of p53, c-erb-B2 and MIB-1 in endometrial carcinoma.
Cherchi PL; Marras V; Capobianco G; Ambrosini G; Piga MD; Fadda GM; Rosas N; Dessole S
Eur J Gynaecol Oncol; 2001; 22(6):451-3. PubMed ID: 11874080
[TBL] [Abstract][Full Text] [Related]
39. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation.
Honda K; Sbisà E; Tullo A; Papeo PA; Saccone C; Poole S; Pignatelli M; Mitry RR; Ding S; Isla A; Davies A; Habib NA
Br J Cancer; 1998 Mar; 77(5):776-82. PubMed ID: 9514057
[TBL] [Abstract][Full Text] [Related]
40. Clinical associations and prognostic significance of serum anti-p53 antibodies in Thai patients with hepatocellular carcinoma.
Tangkijvanich P; Janchai A; Charuruks N; Kullavanijaya P; Theamboonlers A; Hirsch P; Poovorawan Y
Asian Pac J Allergy Immunol; 2000 Dec; 18(4):237-43. PubMed ID: 11316045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
